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Myocardialinfarctionistheleadingcauseofdeathindevelopedcountries.Cardiaccelltherapyhasbeenintroducedtoclinicaltrials
for more than ten years but its results are still controversial. Tissue engineering has addressed some limitations of cell therapy and
appears to be a promising solution for cardiac regeneration. In this review, we would like to summarize the current understanding
about the therapeutic eﬀect of cell therapy and tissue engineering under purview of functional and structural aspects, highlighting
actual roles of each therapy towards clinical application.
1.Introduction
Ischemic heart disease is the principal cause of chronic heart
failure in developed countries. In the USA alone, it causes
400,000 deaths annually [1].
The currently available therapies (i.e., pharmacological,
interventional, and surgical methods) are unable to revitalize
dead myocardium. Therefore, they cannot halt or reverse the
development of congestive heart failure (CHF). Though car-
diomyocytes in nonmammalian vertebrate species, like ze-
braﬁsh, can restore the injured myocardium through prolif-
eration and diﬀerentiation, this mechanism is not signiﬁcant
in humans [2]. Cardiac transplantation, the sole deﬁnitive
therapy with long-term eﬀect for end-stage HF so far, re-
mains limited due to the scarcity of heart donors [3].
Myocardial restoration therapies, including cardiac cell
therapy and cardiac tissue engineering, sound promising for
a failing heart [4] as their ultimate goals are to regenerate the
injured myocardium by robust and viable cells or artiﬁcial
tissues.
Although 10 years passed since Menasche et al. launched
the ﬁrst clinical trial [5], cardiac cell therapy has not become
a well-established medical treatment for postmyocardial in-
farction (MI) patients. Delivery of cell suspensions to the
myocardiumislimitedbyvariousfactors,suchasinsuﬃcient
cell retention and survival [6]. The introduction of cell-cell
mechanical interaction systems, in the form of either cell
sheets or biomaterial scaﬀolds [7] has addressed the issues
related to poor cell retention and survival. Moreover, this
strategy may oﬀer a three-dimensional homogeneous cell
delivery plus structural support (scaﬀold) to the myocardial
area of ischemic injury [7]. Yet, there are no clinical studies
of this approach.
Though both cardiac cell therapy and tissue engineering
have resulted in some improvement of function and struc-
ture of the injured heart, it would still be a laborious mission
to reproduce the “real” myocardium. In this review, we
would like to summarize the latest achievements of regenera-
tivemedicineincardiacrepairandobstaclestowardsarobust
cardiac regeneration, under purview of the cardiac struc-
ture and the postinfarction cardiac remodelling. We per-
formed a Pubmed search with the keywords “cardiac remod-
elling,” “myocardial structure,” “cardiac cell therapy,” “car-
diac tissue engineering,” “myocardial restoration,” and “sur-
gical ventricular restoration.” Relevant references from all
articles reviewed up to June 2011 have been selected for fur-
ther discussion.2 Cardiology Research and Practice
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Figure 1: Contraction mechanism of the heart and ventricular wall remodelling after MI. EF: ejection fraction; ECM: extracellular matrix.
2. The Heart Structureand Post-MI
Remodelling (Figure1)
The challenging features of the myocardial restoration are
the reproduction of the highly angiotropic and anisotropic
three-dimensional muscular structure which has contractile
function and mechanics. The optimal regeneration approach
needs to address all following features of the heart.
Cardiomyocytes (CMs) are a decisive component of a func-
tionalmyocardiumandcontributetothefunctionoftheheart
by their contraction and intercalated anatomical feature.
They are highly resistant to fatigue and rich in myoglobin
and mitochondria, featuring a high metabolic demand.
The ventricular wall is structured in muscular bands. Its
highly asymmetrical and anisotropic architecture facilitates
35–40% increase of thickness of the left ventricular wall in
systole, with only 8% thickening of single myoﬁbers [8]. The
helicalstructureiscrucialfortheproductionofcardiacwork.
The contraction of the muscle cells results in multidirection-
al movement of the ventricular wall, including longitudinal
shortening, spiral movement, and thickening of muscle
bands, which synergistically produce vortex forces and sheer
stresstoejectblood.Asaresult,thespiralassemblycancreate
a left ventricular ejection fraction (LVEF) of 60% with only
15% ﬁbre shortening (Figure 1), while a spherical assembly
would only be capable of an LVEF of 30% [9].
The vascular system of the heart is well developed to meet
theintenseaerobicmetabolismofCMs.Bloodfromthemain
coronary arteries ﬂows through the penetrating arteries of
20–200μm at 1mL per gram of tissue to high dense network
of capillary, almost one capillary per cell, with greater distri-
bution in the subendocardial than subepicardial layer. More-
over, the presence of an adequate coronary ﬂow reserve
allows 3- to-4-fold increase in the coronary ﬂow to meet the
increased metabolic demands. The subendocardial layer is
perfused only in the diastole phases and has a lower reserve.
Also, it suﬀers greater systolic compression and oxygen
demandduetowalltension,whichplaceitatahigherriskfor
dysfunction,tissueinjury,andnecrosisduringischemia[10].
Cardiac remodelling is a progressive change in genomic,
molecular, cellular, and intercellular structures of cardiac
tissue,startingfewhoursafterMIandcontinuingforyears.It
ﬁnally leads to alterations in size, shape, and function of the
heart. Initially, cardiac remodelling is an adaptation of the
heart to retain its function after MI. Impaired contractility
due to lost myocardium is compensated by the increase in
end-diastolic volume in order to restore stroke volume, fol-
lowed by myocyte hypertrophy, cellular elongation, and pro-
liferation [11] .T h eg l o b a lc o m p e n s a t i v ev e n t r i c u l a rh y p e r -
trophy is not accomplished during 1st year post-MI, there-
fore, left ventricular (LV) dilatation and thinning continues
progressively both in infarct and noninfarct area as a con-
sequence of the volume overload and the increase in global
wall tension, according to Laplace’s and Frank-Starling law.
The increase of wall stress further exacerbates energy im-
balance and ischemia, especially in the subendocardial layer,
which lead to the additional apoptosis in the aﬀected area.
The wall tension, as a result of the dilatation and thinning of
ventricular wall, causes even further dilatation. Also, over-
stretching of the ventricular wall and CMs destroys the func-
tional sarcomeres and further impairs contractility. One of
the objectives of myocardial restoration is to stabilize the in-
teraction of sarcomeric CMs and halt or reverse the mala-
daptive LV dilatation. The timing for cardiac remodelling
and the change from an adaptive to a maladaptive process
are not clear and may vary. In consequence, the left ventricle
undergoes wall thinning, chamber dilatation, and reshaping
from the elliptical to spherical form years after onset of MI.Cardiology Research and Practice 3
Patients develop heart failure [12]. Cardiac remodelling is
the key mechanism and predictor of the late adverse out-
come after myocardial infarction [13].
3.MyocardiacRestoration Methodologies
3.1. Cell Therapy. Cell therapy has been applied in clinical
myocardial restoration for almost ten years [5]. Though the
result is still controversial, some studies have shown the
attenuation of the ventricular remodelling. LVEF increased
by 2.99%, the infarct size was reduced by 3.5% [14], and
cardiac adverse events have been reduced at 2 years followup
[15]. It also prevented further dilatation of the left ventricle
[16] and improved the systolic function through reduction
of the left ventricular end-systolic volume by 4.74% [14].
So far, cardiac cell regeneration has proven to be a rela-
tivelysafeclinicaltherapy,anditcanberepeatedlyperformed
as an adjunct treatment to percutaneous coronary inter-
vention (PCI) or coronary artery bypass grafting surgery
(CABG).Therehasbeennoclinicalreportabouttumourfor-
mation. Except for myoblasts injection [5], other cell types
are not associated with malignant arrhythmias. The in-
creased rate of in-stent restenosis was reported with the in-
tracoronary infusion of the CD133+ fraction of bone-mar-
row-derivedstemcell[17]orgranulocytecolony-stimulating
factor (G-CSF) [18].
3.1.1. Cell Types in Cardiac Cell Therapy. Many cell types
have been investigated (Table 1). The primordial concept in
cardiac regeneration was to repopulate the dead CMs with
myogenic cells. Until now, skeletal myoblasts (SKMs), CMs,
and other progenitor cells capable of diﬀerentiation to CMs
like embryonic stem cell (ESC), ESC-derived CMs (ESC-
CMs), and mesenchymal stem cells (MSCs) have been inten-
sely studied.
SKMs showed excellent results in animal [19]a n dw e r e
soon applied in clinical trials [20]. However, poor coupling
with host cells and the resulting arrhythmia are major draw-
backs of this cell type [5]. Nevertheless, SKMs still attract
researchers because of the availability of abundant autolo-
gous cells and myogenicity. In an attempt to improve the
electrical integration of SKMs with host cells, Connexin 43
gene transfection of myoblasts has reduced the arrhythmo-
genicity [21].
TheimmatureCMsextractedfromneonatalratventricles
have been widely studied in animal models of myocardial
infarction. The implantation of CM in post-MI myocardium
has shown long survival, coupling, and integration with host
CMs, as well as contractile activity [22]. Since the CMs soon
terminate hyperplasia and convert to hypertrophy after birth
[23], the source of this cell is questionable when considering
its therapeutic potential. Methods to retain engrafted cell
numbers by an induction of CMs to reenter the cell cycle
are being studied [24]. However, the genetically modiﬁed
cells may pose a safety issue as the risk of tumour formation
wouldarise.Therefore,CMshavenotmadetheirwaytoenter
clinical trials so far.
The successful isolation of cardiac stem cells (CPCs) from
adultmyocardiumhasattractedmuchinterestasapromising
cell source. CPCs are capable of proliferating and diﬀeren-
tiating to CMs and endothelial cells [25]. CPCs have a high
translational potential because they can be harvested by
biopsy during open heart surgery and later expanded in vitro
before implantation. Intracoronary delivery of cardiac stem
cells reduced LV dysfunction after infarction in an animal
model [26] and a clinical trial using this cell type has been
started. Yet, the contractility and adrenergic receptors have
not been found with this cell type and their eﬀect was mainly
attributed to paracrine pathway [27].
Embryonic stem cells are pluripotent cells which can
diﬀerentiate to the true cardiac phenotype [28]. Embryonic-
stem-cell-derived cardiomyocytes matured and survived up-
on injection into rat myocardium and are associated with
lower risk of tumorigenesis [29]. A recent study by Blin et al.
in an immunosuppressed nonhuman primate model showed
puriﬁed SSEA-1+ ESC-CMs diﬀerentiated into ventricular
myocytes and reconstituted 20% of the scar tissue, without
forming teratomas [30]. Safety of utilization of ESC-CMs re-
mainsalimitationastheachievedpurityisatthemostas85–
90%[31].Again,ethicalissuesarestillaconcernwiththiscell
type.
Recently, very small embryonic-like stem cells (VSELs)
were found in very small quantity in peripheral blood, um-
bilical cord blood, and bone marrow (0.02%) [32]. VSELs
showed the markers of ESC and cardiac committed pheno-
type, yet only 7% of puriﬁed VSEL cells are able to form
spheres that resemble embryoid bodies [32]. They can be ex-
panded and diﬀerentiate to the cells of three germ layers sim-
ilar to ESC. Intramyocardial injection of VSELs in a mouse
model of MI, following in vitro expansion and precardiac
diﬀerentiation, showed diﬀerentiation into cardiac pheno-
type with attenuation of cardiac remodelling and improve-
ment of function [33]. No clinical data with VSELs is
available yet.
The introduction of induced pluripotent stem cells
(iPSCs) using genetic technology may help to mitigate con-
cerns surrounding the ethical and the immunologic issues
related to ESCs. iPSCs are stromal cells which are repro-
grammed by transfection with a set of pluripotent transcrip-
tion factors (like OCT3/4. Sox2, c-Myc, Klf-4) that render
them pluripotent ECSs [34]. Utilization of these cells for
cardiac tissue engineering holds great translational potential,
as they could be a patient-speciﬁc autologous cell source.
iPSCs-derived CMs have shown to have properties similar to
ESCs-derived CMs in vitro and, therefore, promise a poten-
tial autologous cardiogenic cell source for myocardial regen-
eration [34]. However, the exact mechanism of reprogram-
ming and their safety relating to transcription factors and
transfection vectors are still unclear, a fact that limits their
clinical utilization.
Bone Marrow-Derived Cells (BMCs). The early report
showed that BMC can transdiﬀerentiate to CMs [35] and it
was soon translated for clinical use. However, the subsequent
studies showed that the diﬀerentiation rate was extraordi-
narily low [36] and the hematopoietic stem cell fraction
followed the hematopoietic fate instead [37]. However,4 Cardiology Research and Practice
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the transplantation of bone-marrow-derived cells, includ-
ing mononuclear cells, mesenchymal stem cells, and BM-
derived circulating progenitor cells, has shown therapeutic
eﬀects. Compared to control groups, BMC transplantation
improvedleftventricularejectionfractionby3.66%,reduced
infarct size by 5.49%, and reduced left ventricular end-
systolicvolumeby4.80mL[38].Theregenerativepotentialof
bone-marrow-derived stemcells via directcell diﬀerentiation
cardiac myocytes is not signiﬁcant [36, 39]. Instead, bone
marrowcellsimplantationimprovedangiogenesis,antiapop-
tosis, recruitment of local or circulating stem cells, and sec-
reted bioactive factors to suppress the local immune system
and inhibit ﬁbrosis [40].Series of clinical trials have applied
bone-marrow-derived stem cells but the results are con-
troversial. So far, intracoronary delivery of bone-marrow-
derived mononuclear cells (BMNC) is the most studied [14].
3.1.2. The Fate of Transplanted Cells. Using the methods of
intracoronary infusion or intramyocardial injection of sus-
pension of cells, cells are delivered randomly into the myo-
cardium. Therefore, it is impossible to control the distribu-
tion of the cells and only 1.3–17.8% of injected cells stay
in infarct area [54]. The majority of cells delivered through
intracoronaryinfusion accumulateinborder zone,not inthe
infarct zone (Figure 1)[ 55].
The retention of cells in the myocardium determines the
therapeutic eﬀect. It depends on local responses, including
inﬂammatory changes, upregulation of chemokines recep-
torsandadhesionmolecules,andtherobustnessofthetrans-
planted cells. In fact, cells delivered in a cell suspension will
be soon washed out by the venous system, the squeezing of
the a heart muscle during systole, and, in case of intramyo-
cardial injection, the leakage through injection holes. There-
fore, 50% of injected cells die and only 2–5% are detected
after 24 hours [56]. Hence, cell retention becomes crucial
in cell therapy [57]. A possible compensation for lost cells
would be to deliver a large quantity of cells.
Cell survival is another concern in a cell therapy. Upon
transplantation, the majority of cells die in the ﬁrst 4 days,
because of ischemia and inﬂammation, and only 5–10% of
cells survive [58, 59].
3.1.3. The Clinical Outcome of Cell Therapy. The clinical
beneﬁt of cell therapy so far is limited and not con-
sistent. In Focus-HF trial, despite having no eﬀect on
cardiac function, autologous bone marrow mononuclear cell
(ABMMNC) therapy signiﬁcantly improved quality of life
at 6 months, Canadian Cardiovascular Society angina score,
and myocardial infusion [48]. Recent results from REPAIR-
AMI trial at 2 years followup showed that intracoronary per-
fusion of autologous bone-marrow-derived progenitor cells
(BMCs) reduced occurrence of major cardiac events, includ-
ing myocardial infarction and revascularization, and im-
proved regional left ventricular contractility of infarcted seg-
mentswhencomparedwithplacebo[15].Ontheotherhand,
the SCAMI trial showed no improvement in function and
size of cardiac chamber after MNC intracoronary infusion
(381×106 cells, 6.1 days after revascularization) when evalu-
ated by cardiac MRI [60], whereas others showed limited
improvement of LVEF [14]. The long-term eﬀect is not su-
perior to traditional pharmacological therapies [12, 61]a n d
there is also obvious change in cardiac remodelling [60].
The eﬀect of cell therapy is more related to paracrine eﬀects,
which operate to salvage the cells after MI rather than in-
duce new functional tissue in or around the infarct area. Fur-
thermore, the cells are randomly implanted and poorly
localized in the infarct area which might make it diﬃcult to
build a macroscopic and organized cluster of cells to sup-
port scarred myocardium. Therefore, the eﬀect is limited to
regional changes, rather than global improvement of cardiac
function and structure.
Nevertheless, cell therapy is still an attractive approach
because it is feasible in minimally invasively and as a ﬁrst-
line therapy in combination with PCI so far. Cell therapy can
be applied in a catheterization laboratory concurrently with
primaryPCIorweekslaterwhentheacuteresponsesubsides,
or in combination with CABG.
Many attempts have been made to tackle the disad-
vantages of cell therapies. Some fractions of bone-marrow-
derived cells, including Cd34+ [62], CD45− [52], Cd133
[63, 64], showed better cell survival and retention than non-
fractioned bone marrow cells. Overexpressing VGEF [65]
or Akt [66] by gene transfection also enhance the cell sur-
vival. The treatment of bone-marrow-derived MSCs with
platelet-derived growth factor BB (PDGF-BB) resulted in
lower rate of apoptosis in vitro and the number of surviving
cells has doubled at day 21 posttransplantation [67]. The
optimal time for cell injection has been sought for. Because
theeﬀectofcelltherapyinchronicMIisverylimited[56,68],
cells should be transplanted as early as possible after MI to
save more cells and prevent remodelling. In contrast, im-
mediate delivery of cells after acute myocardial infarction
results in massive cell death because of the intense inﬂam-
matory reaction. It was shown that injection of cell between
day 5 and 30 after acute MI could oﬀer the better result [38].
In subacute scenario, cells can be delivered during PCI or
CABG. Since more than 90% of cells are lost after trans-
plantation, cell therapy requires a large quantity of cells
(more than 100 milions with bone marrow cells) to make up
for losses and show an improvement of LVEF [14, 69]. Also,
the modest improvement of function and geometry of the
heart with cell therapy may necessitate the investigation of
the other long-term end-points as symptom relief (angina)
or major cardiac events rather than cardiac remodelling.
3.2. Cardiac Tissue Engineering. The aim of tissue engineer-
ing is to replace or support injured tissues through implan-
tation of assembled compounds of cells with degradable
biomaterial scaﬀolds [7].
The matrix provides the physiologic environment, an-
chors the cells, and protects them from the hostile environ-
ment [70]. Optimally, the mechanical support from the bio-
materials persists until the new extracellular matrix (ECM)
is established. The compound of cells and matrix provides
both biological and mechanical support to the ventricular
wall, improves the cardiac function, and decelerates the
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The ultimate goal of cardiac tissue engineering is to build
a large-scale, artiﬁcial myocardium to replace or support the
infarcted area. More than a pure three-dimensional struc-
ture, the challenging artiﬁcial myocardium should be an ani-
sotropic and angiotropic tissue which has rhythm, contrac-
tility, and mechanical durability.
3.2.1. The Approaches to Produce Artiﬁcial Heart Muscle.
With regards to implantation methodology, the artiﬁcial
constructs can be used as epicardial patch or injectable
matrix.
(1) Cardiac Patch
CellSeedinginPorousMaterial. Leoretal.seeded3×105 fetal
rat cardiac cells in a 6×1mm 3D preformed alginate scaﬀold
by dropping of cell suspension on top of this dry hydrophilic
scaﬀold. This cell-scaﬀold construct was cultured in vitro
for 4 days and then implanted in rat, subacutely infarcted
myocardium by suturing on the heart resulting contracting
aggregates. The cells were fed by new network of capillaries
which is connected to the neighbouring coronary system
of host tissue, which might be induced by growth factors
secreted from the implanted embryonic cells.
This degradable porous scaﬀold degraded after nine
weeks and was replaced by the novel ECM. A small number
of myoﬁber bundles was seen embedded among the collagen
ﬁbers, but they were not in full integration with the host
myocardium. However, the graft attenuated LV dilatation
and improved heart function, which might be attributed to
the elastic properties of bioartiﬁcial grafts and angiogenesis
induced by paracrine eﬀects of the embryonic cells and
nonspeciﬁc immune response against the implanted biograft
[71].
Cell Entrapment. The disadvantage of cell seeding is the
irregular distribution of cells within the porous scaﬀold.
Zimmermannetal.introducedthemethodtocreatethecon-
struct by mixing cells with the soluble hydrogel of collagen
type I and extracellular matrix protein (Matrigel) before its
condensation in the casting mold to form a 3D structure
[72, 73]. This approach has some advantages over seed-
ing cells in preformed porous materials. Firstly, uniform
cell distribution can be achieved. Secondly, it facilitates
the mechanical and electrical preconditioning. Zimmerman
et al. manipulated further the construct to generate the
contractile engineered heart tissue (EHT) by continuing in
vitro culture of EHTs for 7 days and then exposing the ring-
shape construct to cyclic mechanical strain for another 7
days. Five EHTs were stacked together to increase the thick-
ness before implantation. As a result, it improved the mech-
anical and electrical integration within host tissue. Neova-
scularisation with connection of capillaries to the host cir-
culation was also observed. The EHT also contributed to the
function of the LV.
Cell Sheet. As c a ﬀold-free approach using cell sheets, devel-
oped by Shimizu et al. in 2003 [74], was taken by culturing
cells in 20–30nm thick poly(N-isopropylacrylamide) dishes.
The newly formed cell sheet can be detached from this
thermoresponsive cell surface when the temperature is re-
duced to below 32 degrees Celsius. The three-dimension cell
sheet was later created by stacking multiple layers.
The initial limitation of only three layers (80μm) was
later improved by diﬀerent strategies, including seeding on
diﬀerent types of membrane, stacking in a sandwich fashion
with endothelial progenitor cell, or repeated transplantation
of triple-layer grafts [75]. The multilayered sheets of car-
diomyocytes showed characteristics of cardiac muscle tissue
with diﬀerentiated sarcomeres and gap junctions as well as
macroscopic contractility [76]. Recently, the cell sheet of my-
oblasts has been applied in clinical trial with encouraging re-
sults [43]. However, regardless the ongoing search for safe
myogenic cell types, it is still questionable that how many
layers of cell can be maximally stacked and if it would be
enough to adequately substitute human myocardium.
(2) Injectable Matrix. The disadvantages of rigid matrices
are the interruption to the continuity of the myocardial ar-
chitecture, signal transfer, vascularisation, and poor syn-
chronization of the graft’s contraction with the host heart
[77, 78]. The liquid matrix has some advantages over the
rigid materials. It can be produced from synthetic, natural,
or decellularized materials. It can comply with the host ar-
chitecture as a framework to scaﬀold the large damaged
structure in order to prevent remodeling. The liquid matrix
oﬀers higher cell viability and retention than the cell sus-
pension. Injectable material alone, without cells, can support
the ventricular wall and prevent wall thinning [79]. The clin-
ical potential of this approach lies in the capability to deliv-
ermatrixtomyocardiumminimallyinvasivelyviaeithertho-
racoscopy or transcatheter. Koﬁdis et al. showed the better
graft/infarct area ratio with injectable matrix + cell (45.5 ±
10.8%) compared with cell alone (29.1 ± 6.7%) in a mouse
myocardial infarction model. The fractional shortening in
the treated group (27.1 ± 5.4) was also signiﬁcantly better
than in the control group (11.9 ± 2.4) [68]. Singelyn et al.
reported injectable matrix from decellularized porcine myo-
cardial tissue which could gel upon injection into rat myo-
cardium and preserve LV volume and ejection fraction [80,
81].
3.2.2. Biological Patch for LV Volume Reduction Surgery. Re-
cently, Miyagi et al. introduced an approach which could be
perceived as intersection between tissue engineering and sur-
gical ventricular restoration (SVR) for the treatment of ven-
tricular aneurysm. The study showed that the combination
of poly-ε-caprolactone-coated gelfoam as a new, reinforced,
biodegradable biomaterial, and cytokine/cell treatment
(stem cell factor, stromal cell-derived factor-1alpha, bone
marrow mesenchymal stem cells) created a viable tissue after
SVR and produced better functional outcome than unrein-
forced gelfoam or modiﬁed gelfoam alone [82].
Whole Heart Reconstruction. Ott et al. have attempted at
rebuilding or reengineering the wholeheart, through decel-
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three-dimensional structure and vasculature. This acellular
heartwas reseededwith cardiomyocytes and endothelial cells
(ECs) and maintained for up to 28 days by coronary per-
fusion in a bioreactor. This construct showed macroscopic
contraction with very low ejection fraction, similar to 2%
of adult or 25% of 16-week fetal heart function [83]. Even
though, this approach does not guarantee the reconstruction
of the real structure of myocardium. As such, randomly
repopulating the decellularized heart with contractile cells
might not be suﬃcient to make it function signiﬁcantly.
3.2.3. Vascularization of the Grafts. The heart is an angio-
tropic organ. It relies on the dense network of vessels to
meet its very high metabolic demand. There is almost one
capillary for every myocyte and the resting blood ﬂow is
about 1mL/gram of heart muscle per minute and it can be
increased to three or four times of normal. Therefore, the
complexcoronarysystemincludingthelargeepicardialcoro-
nary arteries, followed by penetrating arteries and capillary
plexus, is required to maintain the function of the heart [10].
Any artiﬁcial construct with high ﬁdelity to nature needs
to incorporate this feature in its structure. Usually, the thick-
ness of construct is less than few hundred microns because
the cells in the construct only survive within 100–200μm
from the nearest capillary by the diﬀusion of oxygen, nutri-
tion from the medium and later host tissue. As the thicker
artiﬁcial myocardium is required to support the ventricular
wall, it is critical to prevascularize the construct before im-
plantation [84].
Many vascularization strategies at various scales have
been applied in CTE. Pretreatments of the scaﬀold with
ﬁbroblast [85], triple coculture cells (ﬁbroblast, endothelial
cell, and cardiomyocytes) [86], and ascorbic acid [87]h a v e
shownbettercellsurvivalandpromotedvascularization.The
composite cell sheet, fabricated by sandwiching endothelial
cells between the cell sheets, showed improvement in forma-
tion of capillary structure [88].
The abundant blood vessels and availability of omentum
was also exploited in order to mature a vasculature in scaf-
folds [89, 90].
The pedicled grafts would oﬀer clinically relevant vascu-
larization of larger scale engineered tissues as the artiﬁcial
arterial or venous pedicle can be connected to the host coro-
nariesoraortatomaintainconsistentperfusionafterimplan-
tation. The cellular viability and metabolism could be en-
hanced by seeding in the pulsatile perfusion culture platform
introduced by Koﬁdis et al. [91]. The chamber was de-
signed withthecorevesselsofnaturalorigin asrataorta,em-
bedded in scaﬀold made of ﬁbrin glue and neonatal cardi-
omyocytes. After 2 weeks of continuous in vitro pulsatile
perfusion, a solid block of 8mm thick was created. Sig-
niﬁcant improvement of cell survival was seen in perfused
chamber and cells concentrated more in the immediate
vicinity of core vessel [91]. Morritt et al. introduced the
in vivo rat model of AV loop chamber to prevascularize
the graft [84]. Neonatal rat cardiomyocytes in Matrigel
were implanted with an arteriovenous blood vessel loop
into a 0.5-mL patented tissue-engineering chamber, located
subcutaneously in the groin which later form a ∼2mm thick,
contractile vascularised scaﬀold [84]. A vein or synthetic
graft is used to form a shunt loop between an artery and a
vein. The spontaneously contracting product demonstrated
organized assembly, highly vascularization and approached
thickness of 2mm [84].
3.2.4. Clinical Application of Cardiac Tissue Engineering. Pre-
clinical studies have shown the beneﬁt of tissue engineering
over cell therapy, with the signiﬁcant increase of LVEF up to
25%–28% [92, 93]. However, the requirement of a surgical
procedure has hindered its clinical application. Chachques
e ta l .i m p l a n t e da7× 5 × 0.6cm construct epicardially in
10 patients after single-vessel CABG left ventricular end-
diastolic volume evolved from 142.4 ± 24.5mL to 112.9 ±
27.3mL (matrix, P = 0.02) versus 138.9 ± 36.1mL to
148.7±41mL (no matrix, P = 0.57). The scar area thickness
progressed from 6 ± 1.4mm to 9± 1.1mm (matrix, P =
0.005)versus5±1.5mmto6±0.8mm(nomatrix,P = 0.09)
[94]. Recenly, Sawa reported the recovery of cardiac function
after implantation of cell sheet in one patient [43]. Cardiac
tissue engineering as stand-alone therapy would require the
development of appropriate minimally invasive techniques.
3.3. Surgical Ventricular Restoration. In case of dilated left
ventricle after MI, the functioning tissue has to work more,
asFrank-Starlinglawdemands.Thereisalsomoretensionon
thenormalmyocardiumtocompensatetheworkofinfarcted
area, as per Laplace’s law. As a result, the radius of the left
ventricle increases, the thickness decreases, and the heart
becomes spherical. The orientation of muscle ﬁbres changes
towards more horizontal. Subsequently, 15% shortening of
muscle ﬁbres results in only 30% of ejection fraction [9].
Reshaping the heart to an elliptical form would be ben-
eﬁcial. Applying this principle, the Dor’s procedure resulted
intheincreaseofLVEFby12.5%andsoasthelifeexpectancy
of patients [95]. Recently, Ferrazzi et al. introduced the
“horseshoe repair” procedure to preserve left ventricular
compliance, which resulted in the increase of LVEF by 20%
after 6.9 months followup [96]. The results of these surgical
procedures highlight the important role of the structure of
the left ventricle in myocardial infarction.
4. Conclusion
The cardiac architecture is a crucial target in restoration
of cardiac function after myocardial infarction. Cells versus
scaﬀolds alone might not be suﬃcient to restore the complex
structure of infarcted myocardium. Though various cell
types and strategies have been investigated, the therapeutic
eﬀect of cell therapy in myocardial restoration is still limited.
Regardless the disadvantages of cell therapy, such as limited
cell survival and retention and the unknown mechanism of
action,cellsaloneactuallyarenotthedecisivefactorformyo-
cardial restoration as they cannot restore the structure of
the LV, the helix of the heart, the vortex mechanism, and
structural defects which cause the nonischemic expansion
after MI. Tissue engineering has tackled some limitations of
cell therapy. However, its goals so far are to develop con-
structswithamechanicalsupporttotheventricularchamber8 Cardiology Research and Practice
in order to reduce LV dilatation and provide an environment
for transplanted cells favouring cell survival, proliferation,
and diﬀerentiation. Yet, tissue engineering has not addressed
the real anisotropic and helical structure of the heart and its
mechanics.
Myocardial restoration cannot be a monotherapy, but
rather polytherapy, as is heart failure therapy today. It should
be the comprehensive combination between pharmacologi-
caltherapy,surgical,andinterventionalprocedures,cellther-
apy, and tissue engineering on a patient-speciﬁc basis.
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